Advertisement

Tumor Biology

, Volume 34, Issue 4, pp 2383–2388 | Cite as

Association between microsomal epoxide hydrolase 1 polymorphisms and susceptibility to esophageal cancer: a meta-analysis

Research Article

Abstract

Microsomal epoxide hydrolase 1 (EPHX1) plays an important role in the detoxification of carcinogenic polycyclic aromatic hydrocarbons. EPHX1 Tyr113His and His139Arg polymorphisms have been reported to have some impacts on the EPHX1 activity. Previous case–control studies assessing the associations between EPHX1 polymorphisms and esophageal cancer risk reported conflicting results. To quantitatively summarize the associations of EPHX1 Tyr113His and His139Arg polymorphisms with esophageal cancer risk, a systemic review and meta-analysis of published studies were performed. Published literatures from PubMed, Embase, and China National Knowledge Infrastructure databases were searched. The strength of the associations between EPHX1 polymorphisms and esophageal cancer risk was estimated by the pooled odds ratios (ORs) with its 95 % confidence interval (95 %CI). This meta-analysis yielded nine case–control studies, which included nine studies for Tyr113His polymorphism (1,291 cases and 2,120 controls) and seven studies for His139Arg polymorphism (899 cases and 1,615 controls). Overall, meta-analysis showed that EPHX1 Tyr113His polymorphism was not associated with esophageal cancer risk under all genetic models. Meta-analysis of these seven studies for EPHX1 His139Arg polymorphism showed that EPHX1 His139Arg polymorphism was also not associated with esophageal cancer risk under all genetic models. However, subgroup analysis by ethnicity further showed that there was an obvious association between EPHX1 His139Arg polymorphism and decreased risk of esophageal cancer in Caucasians (ArgArg versus HisArg/HisHis: OR = 0.52, 95 %CI 0.27–0.97, P = 0.041). This meta-analysis suggests that EPHX1 His139Arg polymorphism is associated with decreased risk of esophageal cancer in Caucasians. In addition, more studies with large samples are needed to get a more precise estimation on the associations mentioned above.

Keywords

EPHX1 Esophageal cancer Meta-analysis Polymorphisms 

Notes

Conflicts of interest

None

References

  1. 1.
    Wheeler JB, Reed CE. Epidemiology of esophageal cancer. Surg Clin North Am. 2012;92:1077–87.PubMedCrossRefGoogle Scholar
  2. 2.
    Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381:400–12.PubMedCrossRefGoogle Scholar
  3. 3.
    Zandberg DP, Bhargava R, Badin S, Cullen KJ. The role of human papillomavirus in nongenital cancers. CA Cancer J Clin. 2013;63:57–81.PubMedCrossRefGoogle Scholar
  4. 4.
    Denlinger CE, Thompson RK. Molecular basis of esophageal cancer development and progression. Surg Clin North Am. 2012;92:1089–103.PubMedCrossRefGoogle Scholar
  5. 5.
    Moaven O, Raziee HR, Sima HR, Ganji A, Malekzadeh R, A'Rabi A, et al. Interactions between glutathione-S-transferase M1, T1 and P1 polymorphisms and smoking, and increased susceptibility to esophageal squamous cell carcinoma. Cancer Epidemiol. 2010;34:285–90.PubMedCrossRefGoogle Scholar
  6. 6.
    Zhou L, Yuan Q, Yang M. A functional germline variant in the P53 polyadenylation signal and risk of esophageal squamous cell carcinoma. Gene. 2012;506:295–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Zhuo W, Zhang L, Wang Y, Zhu B, Chen Z. Cyclin D1 G870a polymorphism is a risk factor for esophageal cancer among Asians. Cancer Invest. 2012;30:630–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Puranik YG, Birnbaum AK, Marino SE, Ahmed G, Cloyd JC, Remmel RP, et al. Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy. Pharmacogenomics. 2013;14:35–45.PubMedCrossRefGoogle Scholar
  9. 9.
    Wang Q, Pang W, Cui Z, Shi J, Liu Y, Liu B, et al. Upregulation of soluble epoxide hydrolase in proximal tubular cells mediated proteinuria-induced renal damage. Am J Physiol Renal Physiol. 2013;304:F168–176.PubMedCrossRefGoogle Scholar
  10. 10.
    Liu F, Yuan D, Wei Y, Wang W, Yan L, Wen T, et al. Systematic review and meta-analysis of the relationship between ephx1 polymorphisms and colorectal cancer risk. PLoS One. 2012;7:e43821.PubMedCrossRefGoogle Scholar
  11. 11.
    Nisa H, Budhathoki S, Morita M, Toyomura K, Nagano J, Ohnaka K, Kono S, Ueki T, Tanaka M, Kakeji Y, Maehara Y, Okamura T, Ikejiri K, Futami K, Maekawa T, Yasunami Y, Takenaka K, Ichimiya H, Terasaka R: Microsomal epoxide hydrolase polymorphisms, cigarette smoking, and risk of colorectal cancer: the Fukuoka Colorectal Cancer Study. Mol Carcinog. 2012. doi: 10.1002/mc.21897.
  12. 12.
    Liu H, Li HY, Chen HJ, Huang YJ, Zhang S, Wang J. EPHX1 A139G polymorphism and lung cancer risk: a meta-analysis. Tumour Biol. 2013;34:155–63.PubMedCrossRefGoogle Scholar
  13. 13.
    Casson AG, Zheng Z, Chiasson D, MacDonald K, Riddell DC, Guernsey JR, et al. Associations between genetic polymorphisms of phase I and II metabolizing enzymes, p53 and susceptibility to esophageal adenocarcinoma. Cancer Detect Prev. 2003;27:139–46.PubMedCrossRefGoogle Scholar
  14. 14.
    Lin YC, Wu DC, Lee JM, Hsu HK, Kao EL, Yang CH, et al. The association between microsomal epoxide hydrolase genotypes and esophageal squamous-cell-carcinoma in Taiwan: interaction between areca chewing and smoking. Cancer Lett. 2006;237:281–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Jain M, Tilak AR, Upadhyay R, Kumar A, Mittal B. Microsomal epoxide hydrolase (EPHX1), slow (exon 3, 113His) and fast (exon 4, 139Arg) alleles confer susceptibility to squamous cell esophageal cancer. Toxicol Appl Pharmacol. 2008;230:247–51.PubMedCrossRefGoogle Scholar
  16. 16.
    Ihsan R, Chattopadhyay I, Phukan R, Mishra AK, Purkayastha J, Sharma J, et al. Role of epoxide hydrolase 1 gene polymorphisms in esophageal cancer in a high-risk area in India. J Gastroenterol Hepatol. 2010;25:1456–62.PubMedCrossRefGoogle Scholar
  17. 17.
    Dura P, Bregitha CV, Te Morsche RH, Roelofs HM, Kristinsson JO, Wobbes T, et al. EPHX1 polymorphisms do not modify esophageal carcinoma susceptibility in Dutch Caucasians. Oncol Rep. 2012;27:1710–6.PubMedGoogle Scholar
  18. 18.
    Zhang JH, Jin X, Li Y, Wang R, Guo W, Wang N, et al. Epoxide hydrolase Tyr113His polymorphism is not associated with susceptibility to esophageal squamous cell carcinoma in population of North China. World J Gastroenterol. 2003;9:2654–7.PubMedGoogle Scholar
  19. 19.
    Casson AG, Zheng Z, Porter GA, Guernsey DL. Genetic polymorphisms of microsomal epoxide hydroxylase and glutathione S-transferases M1, T1 and P1, interactions with smoking, and risk for esophageal (Barrett) adenocarcinoma. Cancer Detect Prev. 2006;30:423–31.PubMedCrossRefGoogle Scholar
  20. 20.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRefGoogle Scholar
  21. 21.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMedGoogle Scholar
  22. 22.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRefGoogle Scholar
  23. 23.
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRefGoogle Scholar
  24. 24.
    Wang LD, Zheng S, Liu B, Zhou JX, Li YJ, Li JX. CYP1A1, GSTs and mEH polymorphisms and susceptibility to esophageal carcinoma: study of population from a high-incidence area in North China. World J Gastroenterol. 2003;9:1394–7.PubMedGoogle Scholar
  25. 25.
    Kuang G, Jin X, Li Y, Wang R, Guo W, Wang N, et al. Association of epoxide hydrolase Tyr113His polymorphism with susceptibility to esophageal squamous cell carcinoma in population of North China. Chinese Journal of Cancer Prevention and Treatment. 2004;11:685–8.Google Scholar
  26. 26.
    Arand M, Cronin A, Oesch F, Mowbray SL, Jones TA. The telltale structures of epoxide hydrolases. Drug Metab Rev. 2003;35:365–83.PubMedCrossRefGoogle Scholar
  27. 27.
    Newman JW, Morisseau C, Hammock BD. Epoxide hydrolases: their roles and interactions with lipid metabolism. Prog Lipid Res. 2005;44:1–51.PubMedCrossRefGoogle Scholar
  28. 28.
    Wang S, Zhu J, Zhang R, Gu Z. Association between microsomal epoxide hydrolase 1 T113C polymorphism and susceptibility to lung cancer. Tumour Biol. 2013;34:1045–52.PubMedCrossRefGoogle Scholar
  29. 29.
    Zhao ZQ, Guan QK, Yang FY, Zhao P, Zhou B, Chen ZJ. System review and metaanalysis of the relationships between five metabolic gene polymorphisms and colorectal adenoma risk. Tumour Biol. 2012;33:523–35.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  1. 1.Department of Radiation OncologyFudan University Shanghai Cancer CenterShanghaiChina
  2. 2.Department of Oncology, Shanghai Medical CollegeFudan UniversityShanghaiChina
  3. 3.Department of Health Statistics and Social Medicine, School of Public HealthFudan UniversityShanghaiChina

Personalised recommendations